Clinical Trial Update: Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

View source ↗

Summary

This document summarizes an interview-based update from a completed trial of capivasertib plus fulvestrant in HR+/HER2- metastatic breast cancer, highlighting p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Breast Cancer | Status: COMPLETED